CAPR Falls 7.6% After Securities Fraud Lawsuit Notice
Capricor Therapeutics (CAPR) fell 7.6% on Aug 21, 2026 after a law firm publicized a securities fraud class action notice tied to the company’s Deramiocel regulatory narrative.
What Capricor announced
The news wasn’t a product launch or an earnings update — it was a class action lawsuit notice circulated by Glancy Prongay Wolke & Rotter LLP. The notice says a securities fraud case has been filed against Capricor Therapeutics, Inc. on behalf of shareholders.
The allegations focus on statements made between December 17, 2025 and July 26, 2026. According to the notice, the company allegedly adopted changes to a pre-specified statistical analysis plan used to analyze clinical data for Deramiocel, and the FDA allegedly had not agreed to those changes before the company resubmitted the Deramiocel BLA. The notice also claims those issues created a significant risk the FDA could conclude the clinical results did not provide substantial evidence of effectiveness, raising risk to regulatory approval of Deramiocel for Duchenne muscular dystrophy.
What it means for Capricor
A lawsuit notice like this can quickly shift the conversation from “what’s next for the drug” to “what did the company say, and when did it say it.” The core issue highlighted is process and disclosure around how clinical data was analyzed and how that lined up with FDA expectations before resubmission.
If the allegations gain traction, they could increase scrutiny on Capricor’s communications around Deramiocel and the BLA process. Even before any legal outcome, the headline risk alone can weigh on sentiment because it adds uncertainty around both regulatory path and credibility. The notice also signals that the Deramiocel approval story remains tightly linked to how the underlying data and analysis choices are viewed.
How the stock reacted
CAPR sold off early, chopped around intraday, and still finished sharply lower.
| Window | Move |
|---|---|
| 5 min | -7.2% |
| 10 min | -1.0% |
| 30 min | +0.6% |
| 1 hour | +1.8% |
| end of day | -7.6% |
On a market-adjusted basis, CAPR underperformed SPY by -7.6% the same day.